Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. Our scientific results demonstrate activity in the following pathways: BET-Bromodomain (inhibition); Apo A1 (upregulation); Inflammation (downregulation); Fibrosis (downregulation); Blood cancers: MML and AML (suppression of proliferation).

Location

Bäumleingasse 18, 4051 Basel

Facts & figures
  • Type of organization

    Private company

  • Year of foundation

    2007

  • Number of employees in Switzerland

    1-9

Key business